Quantcast
Home > Quotes > MNKD

MannKind Corporation Common Stock (MNKD) Quote & Summary Data

MNKD 
$1.74
*  
0.02
1.16%
Get MNKD Alerts
*Delayed - data as of Dec. 11, 2018  -  Find a broker to begin trading MNKD now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 1.77 / $ 1.69
Share Volume
1,638,538
50 Day Avg. Daily Volume
2,150,026
Previous Close
$ 1.72
52 Week High / Low
$ 4.05 / $ 0.9801
Market Cap
277,699,777
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
1,638,538
50 Day Avg. Daily Volume:
2,150,026

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.85

Trading Range

The current last sale of $1.74 is 77.53% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.77 $ 4.05
 Low: $ 1.69 $ 0.9801

Company Description (as filed with the SEC)

Unless the context requires otherwise, the words "MannKind," "we," "Company," "us" and "our" refer to MannKind Corporation and its subsidiaries. We are a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Our only approved product, Afrezza (insulin human [rDNA origin]) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration ("FDA") in June of 2014 to improve glycemic control in adult patients with diabetes. Afrezza became available by prescription in U.S. retail pharmacies in February 2015. According to the Centers for Disease Control and Prevention, 30.3 million people in the United States had diabetes in 2015.  ... More ...  


Risk Grade

Where does MNKD fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.72
Open Date:
Dec. 11, 2018
Close Price:
$ 1.74
Close Date:
Dec. 11, 2018

Consensus Recommendation

Analyst Info